IP International Journal of Comprehensive and Advanced Pharmacology 2020;5(2):87–90 Content available at: iponlinejournal.com IP International Journal of Comprehensive and Advanced Pharmacology Journal homepage: www.ipinnovative.com Original Research Article Improvement in glycemic level with saxagliptin in patients of type 2 diabetes mellitus who were previously on metformin monotherapy with uncontrolled diabetes Akshay Dahiwele 1 , Dinesh K Kansal 2, *, Dheeraj Kapoor 3 , Parveen Sharma 4 1 Medical Services Department (Themis)medicare, India 2 Dept. of Pharmacology, Dr. Rajendra Prasad Govt. Medical College, Tanda, Himachal Pradesh, India 3 Dept. of Medicine, Dr. Rajendra Prasad Govt. Medical College, Tanda, Himachal Pradesh, India 4 Dept. of Pharmacology, Dr. Lal Bahadur Shastri Govt. Medical College, Mandi, Himachal Pradesh, India ARTICLE INFO Article history: Received 26-04-2020 Accepted 07-05-2020 Available online 25-07-2020 Keywords: Saxagliptin Uncontrolled type 2DM Efficacy ABSTRACT Introduction: Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides a secondary mechanism of action to decrease hyperglycemia when used in combination with metformin. In this study we have tried to assess the efficacy of saxagliptin in patients of type 2 DM. Materials and Methods: A total of 35 patients were enrolled who were on metformin monotherapy and with uncontrolled diabetes. Patients were given saxagliptin 2.5 mg once a day. Patients were followed up at 1st, 3rd and 6th month and HbA1c, FPG and 2h-PG estimation was done during the follow up period. Results: The mean age ± SD in male and female patients was 61.42 yrs ± 6.99 and 55.93 yrs ± 5.74 respectively. The mean change in value from baseline at 24 weeks was 10.7%, 16.48% and 21.63% for HbA1c, FPG and 2h-PG respectively and 20% of patient had achieved HbA1c <7%. A highly significant difference has been seen at 0 v/s 1, 0 v/s 3 and 0 v/s 6 months in HbA1c, FPG and 2h-PG values. Conclusion: Saxagliptin has shown an improvement in glycemic index (HbA1c, FPG, 2h-PG) during 6 months of treatment in patients of type 2 DM. © 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/) 1. Introduction Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. 1 In early type 2 DM, symptoms may be more subtle and consist of fatigue, poor wound healing, and paresthesias. The lack of symptoms is the main reason for the delayed diagnosis of type 2 DM. Many pts are diagnosed based on screening or during blood tests taken for other reasons. 2 This delay in diagnosing the disease results in a high prevalence of chronic complications at the * Corresponding author. E-mail address: dinesh.kansal56@gmail.com (D. K. Kansal). time of actual diagnosis, thus when Type 2 diabetes is diagnosed, cardiovascular disease and neuropathy are found in approximately 10% of cases, and retinopathy and nephropathy in 15-20%. 3 The prevalence of type 2 diabetes has been increasing steadily all over the world. As a result of this trend, it is fast becoming an epidemic in some countries of the world with the number of people affected expected to double in the next decade due to increase in ageing population, thereby adding to the already existing burden for healthcare providers, especially in poorly developed countries. 4 The greatest increase in the prevalence of diabetes mellitus is reported from low and middle-income countries. 5,6 Asia, being the epicenter for the epidemics of diabetes, is responsible for more than 60% of the https://doi.org/10.18231/j.ijcaap.2020.019 2581-5555/© 2020 Innovative Publication, All rights reserved. 87